PDSB PDS Biotechnology
- 2.090
- -0.110-5.00%
- 2.090
- +0.000+0.00%
PDS Biotechnology News
Earnings Preview: PDSB to Report Financial Results on November 14
$PDS Biotechnology(PDSB.US)$ is scheduled to release its financial results on November 14 ET. Earnings PreviewAnalysts estimate $PDS Biotechnology(PDSB.US)$ to post revenue of USD0 for 2024Q3, EPS
PDS Biotechnology Price Target Maintained With a $21.00/Share by HC Wainwright & Co.
Noble Financial Maintains PDS Biotechnology(PDSB.US) With Buy Rating, Maintains Target Price $17
PDS Biotechnology: Strategic Advancements and Clinical Progress Drive Buy Rating
PDS Biotechnology | 10-Q: Q3 2024 Earnings Report
12 Health Care Stocks Moving In Thursday's Pre-Market Session
PDS Biotechnology Shares Down 18% After Phase 3 Trial Modifications
PDS Biotechnology Shares Are Trading Lower After the Company Reported Worse-than-expected Q3 Financial Results.
PDS Biotechnology Corporation (PDSB) Q3 2024 Earnings Call Transcript Summary
PDS Biotechnology Corporation (PDSB) Q3 2024 Earnings Call Transcript
PDS Biotechnology | 8-K: PDS Biotech Provides Clinical Programs Update and Reports Third Quarter 2024 Financial Results
Express News | PDS Biotech Provides Clinical Programs Update and Reports Third Quarter 2024 Financial Results
Express News | PDS Biotechnology Q3 Net Income USD -10.7 Million
Press Release: PDS Biotech Provides Clinical Programs Update and Reports Third Quarter 2024 Financial Results
Express News | PDS Biotechnology Q3 EPS USD -0.29 Vs. IBES Estimate USD -0.28
Earnings Scheduled For November 14, 2024
Here's the Major Earnings Before the Open Tomorrow
Uncovering Potential: PDS Biotechnology's Earnings Preview
Buy Recommendation for PDS Biotechnology Based on Promising Prostate Cancer Therapy
PDS Biotech Announces Presentation of Rationale and Design of First Recurrent Prostate Cancer Trial to Combine an Androgen Receptor Pathway Inhibitor With an Immunocytokine
Analysis
Price Target
No Data
No Data